Medicare Enrolled

Dr. Alexei Arkhipov, M.D.

Hematology & Oncology · San Antonio, TX
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
88 BRIGGS ST STE 280, San Antonio, TX 78224
2109221977
In practice since 2006 (19 years)
NPI: 1700980299 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Arkhipov from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Arkhipov? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Arkhipov

Dr. Alexei Arkhipov is a hematology & oncology specialist in San Antonio, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Arkhipov performed 1,816 Medicare services across 336 unique beneficiaries.

Between the years covered by Open Payments, Dr. Arkhipov received a total of $15,378 from 55 pharmaceutical and/or device companies across 651 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Arkhipov is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 44% volume in TX $15,378 industry payments

Medicare Practice Summary

Medicare Utilization ↗
1,816
Medicare services
Top 44% in TX for hematology & oncology
336
Unique beneficiaries
$70
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~96 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Hospital follow-up visit, moderate complexity 1,456 $61 $108
Initial hospital admission, high complexity 139 $132 $300
Office visit, established patient, complex (40-54 min) 87 $135 $194
Complete blood count (CBC) with differential 53 $8 $34
Office visit, established patient (30-39 min) 39 $90 $137
Office visit, established patient (20-29 min) 28 $69 $97
New patient office visit, complex (60-74 min) 14 $156 $216
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$15,378
Total received (2018-2024)
Avg $2,197/year across 7 years
Top 25% in TX for hematology & oncology
55
Companies
651
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$14,634 (95.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$594 (3.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$150 (1.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,990
2023
$2,832
2022
$2,575
2021
$2,622
2020
$2,007
2019
$1,873
2018
$1,478

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$2,008
Novartis Pharmaceuticals Corporation
$1,740
PFIZER INC.
$1,732
Janssen Pharmaceuticals, Inc
$1,465
E.R. Squibb & Sons, L.L.C.
$1,241
AstraZeneca Pharmaceuticals LP
$804
Daiichi Sankyo Inc.
$513
GlaxoSmithKline, LLC.
$414
Dova Pharmaceuticals
$384
Merck Sharp & Dohme Corporation
$382
Boehringer Ingelheim Pharmaceuticals, Inc.
$349
Merck Sharp & Dohme LLC
$336
ARRAY BIOPHARMA INC
$319
Celgene Corporation
$312
GENZYME CORPORATION
$232
Incyte Corporation
$208
Astellas Pharma US Inc
$177
Rigel Pharmaceuticals, Inc.
$167
SOBI, INC
$159
Teva Pharmaceuticals USA, Inc.
$155
COMSORT, Inc
$150
Bayer HealthCare Pharmaceuticals Inc.
$145
Takeda Pharmaceuticals U.S.A., Inc.
$132
TerSera Therapeutics LLC
$128
Pharmacyclics LLC, An AbbVie Company
$127
Janssen Scientific Affairs, LLC
$118
Gilead Sciences, Inc.
$116
Eisai Inc.
$105
Jazz Pharmaceuticals Inc.
$94
ADC Therapeutics America, Inc.
$94
Shield Therapeutics Inc
$94
CSL Behring
$90
Lilly USA, LLC
$78
AMAG Pharmaceuticals, Inc.
$73
Helsinn Therapeutics (U.S.), Inc.
$64
Sobi, Inc
$61
Bayer Healthcare Pharmaceuticals Inc.
$57
Aveo Pharmaceuticals, Inc.
$52
AVEO Pharmaceuticals, Inc.
$50
EISAI INC.
$49
Foundation Medicine, Inc.
$49
Exelixis Inc.
$48
Global Blood Therapeutics, Inc.
$42
Amgen Inc.
$42
Genentech USA, Inc.
$34
Genmab U.S., Inc.
$33
Novo Nordisk Inc
$24
Seagen Inc.
$23
SHIELD THERAPEUTICS INC
$22
CTI BioPharma Corp.
$16
Heron Therapeutics, Inc.
$16
Boston Scientific Corporation
$15
Ipsen Biopharmaceuticals, Inc
$15
PUMA BIOTECHNOLOGY, INC.
$14
Tactile Systems Technology Inc
$13
Top 3 companies account for 35.6% of total payments
Associated products mentioned in payments ›
ACCRUFER · AKYNZEO · Afstyla · BALVERSA · BAVENCIO · BENDEKA · BLENREP · BOSULIF · BRAFTOVI · CABLIVI · CALQUENCE · CARVYKTI · CYRAMZA · Cabometyx · Cinvanti · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · ENJAYMO · ERLEADA · Enhertu · Epkinly · Erleada · Esperoct · FERAHEME · FLEXITOUCH · FOTIVDA · FOUNDATIONONE · Fabhalta · GAZYVA · GILOTRIF · IBRANCE · ICLUSIG · IMBRUVICA · INLYTA · INVOKANA · Idelvion · Imbruvica · JADENU · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MYLOTARG · NERLYNX · NINLARO · Nplate · Nubeqa · OJJAARA · OPDIVO · OXBRYTA · PADCEV · PIQRAY · PROMACTA · Pomalyst · REBLOZYL · RYBREVANT · RYDAPT · Rezlidhia · SARCLISA · SCEMBLIX · SHINGRIX · SOMATULINE DEPOT · SPRYCEL · Stivarga · TAGRISSO · TALZENNA · TASIGNA · TECVAYLI · TIVDAK · Tavalisse · TheraSphere Y90 Glass Microspheres 10 GBq · Trodelvy · VENCLEXTA · VERZENIO · Vonjo · XALKORI · XARELTO · XTANDI · Xermelo · ZEJULA · ZEPZELCA · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (95%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $847 per 100 Medicare services performed
Looking for a hematology & oncology specialist in San Antonio?
Compare hematology & oncology specialists in the San Antonio area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
56
Per 100K population
2.7
County median income
$70,571
Nearest hospital
CHILDREN'S HOSPITAL OF SAN ANTONIO
7.8 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Arkhipov is a mixed practice specialist, with moderate Medicare volume, with low-engagement industry engagement, with 19 years of NPI registration.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Arkhipov experienced with hospital follow-up visit, moderate complexity?
Based on Medicare claims data, Dr. Arkhipov performed 1,456 hospital follow-up visit, moderate complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Arkhipov receive payments from pharmaceutical companies?
Yes. Dr. Arkhipov received a total of $15,378 from 55 companies across 651 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Arkhipov's costs compare to other hematology & oncology specialists in San Antonio?
Dr. Arkhipov's average Medicare payment per service is $70. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Arkhipov) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →